<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7162773\results\search\testTrace\results.xml">
  <result pre="in China included rapid sequencing of the virus to establish" exact="testing" post="kits, which allowed tracking of infected persons in and"/>
  <result pre="infected persons in and out of Wuhan. In addition, aggressive" exact="quarantine" post="measures included the complete isolation of Wuhan and then"/>
  <result pre="of Wuhan. In addition, aggressive quarantine measures included the complete" exact="isolation" post="of Wuhan and then later Hubei Province and the"/>
  <result pre="trials. In the end, it was the enforcement of drastic" exact="quarantine" post="measures that stopped SARS-CoV-2 from spreading. The earlier the"/>
  <result pre="of infected individuals, carriers, and contacts and early implementation of" exact="quarantine" post="measures with an organised, proactive, and unified strategy at"/>
  <result pre="a nationwide directive from the central government, governmental oversight, free" exact="testing" post="(nucleic acid assay, gene sequencing, and IgM-IgG serology), free"/>
  <result pre="and the transfer of resources to the epicenter of the" exact="infection" post="in Hubei Province. Very early, on January 23, 2020,"/>
  <result pre="SARS-CoV-2 was shared with the WHO. Several rapid and sensitive" exact="detection" post="tests were developed by the China CDC. On January"/>
  <result pre="the first of 7 versions of the protocol for the" exact="diagnosis" post="and treatment of COVID-19. On January 20, 2020, the"/>
  <result pre="of 7 versions of the protocol for the diagnosis and" exact="treatment" post="of COVID-19. On January 20, 2020, the NHC upgraded"/>
  <result pre="On January 24, 2020, the local government planned 2 new" exact="quarantine" post="hospitals with 1000 and 1600 beds to be constructed"/>
  <result pre="standardized fever clinics to timely screen for fever and strengthen" exact="isolation" post="management. Designated hospitals were increased as needed by conversion"/>
  <result pre="increases of production (Supplemental Appendix S1; Supplemental Fig.Â S1). 5)Testingâ€&quot;Early" exact="testing" post="provided the basis for tracking and isolation in Wuhan"/>
  <result pre="Fig.Â S1). 5)Testingâ€&quot;Early testing provided the basis for tracking and" exact="isolation" post="in Wuhan to identify persons who could potentially spread"/>
  <result pre="of COVID-19 was rooted in the tracking strategy. All patients" exact="testing" post="positive for COVID-19 were tracked and their contacts isolated."/>
  <result pre="Big data and artificial intelligence (AI) were used to strengthen" exact="contact tracing" post="and the management of priority populations. 7)Temperature screeningâ€&quot;Temperature screening"/>
  <result pre="data and artificial intelligence (AI) were used to strengthen contact" exact="tracing" post="and the management of priority populations. 7)Temperature screeningâ€&quot;Temperature screening"/>
  <result pre="contact tracing and the management of priority populations. 7)Temperature screeningâ€&quot;Temperature" exact="screening" post="checkpoints were established at supermarkets, residential area entrances, and"/>
  <result pre="Everyone was screened for temperature when entering public areas. Temperature" exact="screening" post="is a cheap, easily implemented, and rapid method of"/>
  <result pre="screening is a cheap, easily implemented, and rapid method of" exact="screening" post="large numbers of the population for possible COVID-19. Fever"/>
  <result pre="the nursing work for patients, including daily care, disinfecting the" exact="isolation" post="areas, etc. Nurse 4 was the team leader, who"/>
  <result pre="classification Physicians classified the disease severity of patients with SARS-CoV-2" exact="infection" post="according to the â€œDiagnosis and Treatment Protocol for Novel"/>
  <result pre="nonpregnant women with COVID-19 infection.22TableÂ 1 COVID-19 clinical classification and" exact="treatment" post="recommendations Classification WHO interim guidance21 Chinese clinical guideline20,89 Treatment"/>
  <result pre="Chinese clinical guideline20,89 Treatment recommendations Adult Child Adult Child Asymptomatic" exact="infection" post="NA NA NA Laboratory-confirmed patients without any clinical symptoms"/>
  <result pre="sign of pneumonia on imaging General treatment, symptomatic treatment, antiviral" exact="treatment" post="Moderate Adult with pneumonia but no signs of severe"/>
  <result pre="breastfeed or drink, lethargy or unconsciousness, or convulsions. Although the" exact="diagnosis" post="is made on clinical grounds, chest imaging may identify"/>
  <result pre="to suspected or proven infectionâˆ—âˆ— Children with suspected or proven" exact="infection" post="and â‰¥ 2 age-based systemic inflammatory response syndrome criteria,"/>
  <result pre="high lactate, or hyperbilirubinemia. Nonpharmacologic Treatmentâ€&quot;Supportive and Symptomatic Care General" exact="treatment" post="Symptomatic and supportive treatment is essential and the main"/>
  <result pre="Nonpharmacologic Treatmentâ€&quot;Supportive and Symptomatic Care General treatment Symptomatic and supportive" exact="treatment" post="is essential and the main treatment for COVID-19.20 General"/>
  <result pre="treatment Symptomatic and supportive treatment is essential and the main" exact="treatment" post="for COVID-19.20 General supportive measures for SARS-CoV-2â€&quot;infected patients include"/>
  <result pre="173 53 52 36 13 Treatment, n (%) Â Antiviral" exact="treatment" post="80 (46.2) 52 (98.1) 23 (44.2) 34 (94.4) 12"/>
  <result pre="52 (98.1) 23 (44.2) 34 (94.4) 12 (92.3) Â Antibiotic" exact="treatment" post="139 (80.3) 53 (100) 49 (94.2) NA 13 (100)"/>
  <result pre="(80.3) 53 (100) 49 (94.2) NA 13 (100) Â Corticosteroid" exact="treatment" post="77 (44.5) 37 (69.8) 30 (57.7) 26 (72.2) 6"/>
  <result pre="oxygen therapy be given to patients with severe acute respiratory" exact="infection" post="(SARI), respiratory distress, hypoxemia, or shock.21 However, there are"/>
  <result pre="of invasive mechanical ventilation is an important component of the" exact="treatment" post="of severe respiratory failure and acute respiratory distress syndrome"/>
  <result pre="and influenza has been controversial.35 Pharmacologic agents We summarize the" exact="treatment" post="of 327 pooled cases of severe cases with COVID-19"/>
  <result pre="may or may not be helpful in treating COVID-19. Antiviral" exact="treatment" post="At present, there is no evidence to support the"/>
  <result pre="drugs for COVID-19, although these are commonly used in the" exact="treatment" post="of COVID-19 in China. The guidelines of the NHC"/>
  <result pre="each time, twice per day for adults. The course of" exact="treatment" post="should be â‰¤ 10 days.For children,âˆ— weight 7-15 kg,"/>
  <result pre="time, intravenous injection 2-3 times per day. The course of" exact="treatment" post="should be â‰¤ 10 days.For children,âˆ— 10 mg/kg per"/>
  <result pre="mg for adults, 3 times per day. The course of" exact="treatment" post="should be â‰¤ 10 days. Medication for special populations"/>
  <result pre="women Unclear Approved indications Broad-spectrum antiviral, immunomodulatory, and antitumor HIV-1" exact="infection" post="Respiratory syncytial virus pneumonia Malaria A and B influenza"/>
  <result pre="treatment, including oseltamivir, ganciclovir, and lopinavir/ritonavir.38 The duration of antiviral" exact="treatment" post="was 3-14 days.38 However, the results of a clinical"/>
  <result pre="COVID-19.39 Remdesivir may have the greatest potential for the successful" exact="treatment" post="of SARS-CoV-2, but efficacy and safety in COVID-19 need"/>
  <result pre="trials to treat COVID-19 in China. Favipiravir was approved for" exact="treatment" post="of influenza on February 15, 2020, in China and"/>
  <result pre="time to viral clearance was 4 days in the favipiravir" exact="treatment" post="group compared with 11 days in the lopinavir/ritonavir treatment"/>
  <result pre="favipiravir treatment group compared with 11 days in the lopinavir/ritonavir" exact="treatment" post="group (P &amp;lt; 0.001). In terms of chest imaging,"/>
  <result pre="terms of chest imaging, the improvement rates of the favipiravir" exact="treatment" post="group and the lopinavir/ritonavir treatment group were 91.4% and"/>
  <result pre="improvement rates of the favipiravir treatment group and the lopinavir/ritonavir" exact="treatment" post="group were 91.4% and 62.2%, respectively. No significant adverse"/>
  <result pre="respectively. No significant adverse reactions were noted in the favipiravir" exact="treatment" post="group, and there were significantly fewer adverse effects than"/>
  <result pre="vitro studies, chloroquine and hydroxychloroquine were found to inhibit SARS-CoV-2" exact="infection" post="efficiently,40,44 and several clinical trials have been quickly conducted"/>
  <result pre="NHC (trial version 2) includes convalescent plasma as a potential" exact="treatment" post="in severe cases, critical cases, and cases of rapidly"/>
  <result pre="Registry to study the safety and efficacy of convalescent plasma" exact="treatment" post="in COVID-19 patients.61 Intravenous immunoglobulin In Guan etÂ al.â€™s"/>
  <result pre="173 severe COVID-19 cases, 58 patients (33.4%) received intravenous immunoglobulin" exact="treatment" post="(IVIG). IVIG was considered as a potential therapy for"/>
  <result pre="released at this time. Other pharmaceutical measures Traditional Chinese medicine" exact="treatment" post="The potentially beneficial role of traditional Chinese medicine is"/>
  <result pre="medicine prescriptions and 157 forms of constituent medicines for COVID-19" exact="treatment" post="and found that they may be effective in reducing"/>
  <result pre="target main protease, suggesting their potential for COVID-19 treatment.65 Other" exact="treatment" post="measures According to the guidelines of the NHC,10 vasoactive"/>
  <result pre="critical cases with severe inflammatory reactions.67 In addition to the" exact="treatment" post="of the patientsâ€™ physical condition, psychologic support was provided"/>
  <result pre="controversial. There is no current recommendation to discontinue ARBs during" exact="treatment" post="of COVID-19 in China. Monteil etÂ al. found that"/>
  <result pre="of COVID-19 in China. Monteil etÂ al. found that SARS-CoV-2" exact="infection" post="in engineered human blood vessel organoids and human kidney"/>
  <result pre="ST-segment-elevation myocardial infarction (STEMI) in patients with confirmed COVID-19, strict" exact="isolation" post="should start immediately and thrombolytic contraindications should be evaluated."/>
  <result pre="entire country Measure Content Specific limitations â€¢Strict travel restriction â€¢Mandatory" exact="quarantine" post="â€¢Restrict public transportation â€¢Close schools and entertainment venues â€¢Shutdown"/>
  <result pre="of the Peopleâ€™s Republic of China on the prevention and" exact="treatment" post="of infectious diseases,â€� â€œSurveillance protocol for pneumonia cases from"/>
  <result pre="sites,â€� â€œProvisions on the emergency handling of entry-exit inspection and" exact="quarantine" post="for public health emergencies at border ports,â€� etc. Required"/>
  <result pre="public health emergencies at border ports,â€� etc. Required measures â€¢Temperature" exact="screening" post="on the public occasions, such as hospitals, supermarkets â€¢Purchasing"/>
  <result pre="the virus needs to be isolated, the genome sequenced, and" exact="testing" post="kits validated and released for rapid distribution. Infected individuals"/>
  <result pre="oneâ€™s electronic device. The lesson here is that if effective" exact="quarantine" post="is what needs to occur, these measures must be"/>
  <result pre="areas, both preventing internal and external spread was implemented, and" exact="screening" post="of body temperature and disinfection of public facilities was"/>
  <result pre="closed, but other business activities resumed. In high-risk areas, strict" exact="quarantine" post="and control measures were continued, with continued closure of"/>
  <result pre="strategy in China was early testing, diligent tracking, and strict" exact="isolation" post="of patients and contacts, first in Wuhan and then"/>
  <result pre="of the 2019 novel coronavirus (2019-nCoV)?PLoS Pathog162020e100842132407364 8RotheC.SchunkM.SothmannP.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyN Engl J Med382202097097132003551"/>
  <result pre="Control CenterPractice for management of pediatric ward and prevention of" exact="infection" post="during the epidemic period of COVID-19Chin J Appl Clin"/>
  <result pre="Health Commission of the People's Republic of China. Diagnosis and" exact="treatment" post="protocol for novel coronavirus pneumonia (trial version 7)2020World Health"/>
  <result pre="2020. 21World Health Organisation. Clinical management of severe acute respiratory" exact="infection" post="(SARI) when COVID-19 disease is suspected. 2020. Available at:"/>
  <result pre="2020. 22ChenH.GuoJ.WangC.Clinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: a retrospective review of medical"/>
  <result pre="Hospital Association Of Critical Care Medicine. [Chinese experts' consensus on" exact="diagnosis" post="and treatment of severe and critical coronavirus disease 2019"/>
  <result pre="Of Critical Care Medicine. [Chinese experts' consensus on diagnosis and" exact="treatment" post="of severe and critical coronavirus disease 2019 (Revised Edition)]."/>
  <result pre="with community-acquired severe respiratory viral infectionIntensive Care Med46202031532832040667 36ChenZ.ShuQ.WangDiagnosis and" exact="treatment" post="recommendation for pediatric coronavirus disease-19 (the second edition)J Zhejiang"/>
  <result pre="the recently emerged novel coronavirus (2019-nCoV) inÂ vitroCell Res30202026927132020029 41LuH.Drug" exact="treatment" post="options for the 2019-new coronavirus (2019-nCoV)Biosci Trends142020697131996494 42DongL.HuS.GaoJ.Discovering drugs"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="inÂ vitroCell Discov620201632194981 45GaoJ.TianZ.YangX.Breakthrough: chloroquine phosphate has shown apparent"/>
  <result pre="vitroCell Discov620201632194981 45GaoJ.TianZ.YangX.Breakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBiosci Trends142020727332074550 46Multicenter"/>
  <result pre="Novel Coronavirus Pneumonia. [Expert consensus on chloroquine phosphate for the" exact="treatment" post="of novel coronavirus pneumonia]Zhonghua Jie He He Hu Xi"/>
  <result pre="a recommendation to examine the effect of hydroxychloroquine in preventing" exact="infection" post="and progression [e-pub before print]. J Antimicrob Chemother, 10.1093/jac/dkaa114."/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [e-pub"/>
  <result pre="Infect Dis, doi: 10.1093/cid/ciaa237. 49RussellC.D.MillarJ.E.BaillieJ.K.Clinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injuryLancet395202047347532043983 50ShangL.ZhaoJ.HuY.DuR.CaoB.On the use of corticosteroids"/>
  <result pre="Clin Infect Dis202043 53WangY.JiangW.HeQ.Early, low-dose and short-term application of corticosteroid" exact="treatment" post="in patients with severe COVID-19 pneumonia: single-center experience from"/>
  <result pre="Treatment of MERS-CoV: information for clinicians clinical decision-making support for" exact="treatment" post="of MERS-CoV patients. London: 2014, Public Health England. 58Mair-JenkinsJ.Saavedra-CamposM.BaillieJ.K.The"/>
  <result pre="58Mair-JenkinsJ.Saavedra-CamposM.BaillieJ.K.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
  <result pre="59China National Health Commission. The clinical guideline of convalescent plasma" exact="treatment" post="(trial version 2). 2020. Available at: http://www.chinadaily.com.cn/a/202002/16/WS5e48cbf6a310128217277d72.html. Accessed February"/>
  <result pre="and efficacy of traditional Chinese medicine in staging prevention and" exact="treatment" post="of corona virus disease 2019Zhongguo Zhong Yao Za Zhi45202012531258[in"/>
  <result pre="Expert Team of Chinese Medical Association Nephrology BranchExpert consensus on" exact="diagnosis" post="and treatment of 2019 novel coronavirus (2019-nCoV) infection with"/>
  <result pre="of Chinese Medical Association Nephrology BranchExpert consensus on diagnosis and" exact="treatment" post="of 2019 novel coronavirus (2019-nCoV) infection with acute kidney"/>
  <result pre="consensus on diagnosis and treatment of 2019 novel coronavirus (2019-nCoV)" exact="infection" post="with acute kidney injuryChin J Nephrol2020242246 67LiL.Translation: Expert consensus"/>
  <result pre="the application of artificial liver blood purification system in the" exact="treatment" post="of severe and critical COVID-19: National Clinical Research Center"/>
  <result pre="73XuY.DengX.HanY.AÂ multicenter retrospective review of prone position ventilation (PPV) in" exact="treatment" post="of severe human H7N9 avian fluPLoS One102015e0136520 74Nursing Department"/>
  <result pre="Med 2020;8:P420-2. 77YangP.ShaoF.WangG.Two cases of increased positive rate of SARS-CoV-2" exact="nucleic acid test" post="by aerosol inhalation to induce sputum excretionChin J Tuberc"/>
  <result pre="Disease Group, Respiratory Disease Branch, Chinese Medical AssociationGuidelines for the" exact="diagnosis" post="and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in"/>
  <result pre="Respiratory Disease Branch, Chinese Medical AssociationGuidelines for the diagnosis and" exact="treatment" post="of hospital-acquired pneumonia and ventilator-associated pneumonia in adult in"/>
  <result pre="and control implementation scheme]Available at:http://www.cq.gov.cn/zwgk/fdzdgknr/lzyj/qtgw/202002/t20200219_5273455.htmlAccessed February 19, 2020 89Yi JiangY.LuX.JinR.Diagnosis," exact="treatment" post="and prevention of 2019 novel coronavirus infection in children:"/>
  <result pre="2020 89Yi JiangY.LuX.JinR.Diagnosis, treatment and prevention of 2019 novel coronavirus" exact="infection" post="in children: experts' consensus statement (Second Edition). [J]Chinese Journal"/>
 </snippets>
</snippetsTree>
